Brand and Other Names:Visudyne
- Classes: Macular Degeneration Agents
Dosing & Uses
Dosage Forms & Strengths
lyophylized power for reconstitution
Macular Degeneration with Classic Subfoveal Choroidal Neovascularization
Follow with 50 J/cm² of 689 nm laser light on retina at intensity of 600 mW/cm² x 83 sec
After IV infusion, eyedrops are used to numb eye
Approximately 15 min after infusion & no later than 5 min after eyedrop application, a special ophthalmic lens is placed over eye
Next the cold laser light spot-sized to match treatment area is applied
Central Serous Chorioretinopathy (Orphan)
Designation for the potential treatment of chronic or recurrent central serous chorioretinopathy
- QLT Inc.; Vancouver, British Columbia, Canada
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Determined
Injection site reactions including extravasation and rashes
Flashes of light
Severe vision loss (1-4%)
Subretinal or vitreous hemorrhage
Back pain during infusion
Peripheral vascular disorder
Leukocyte count increase/decrease
Increased liver function test results
Increased serum creatinine
Avoid bright light for 5 days after injection
Moderate/severe hepatic impairment
Chest pain, hypersensitivity, and vasovagal reactions reported (observe patient during infusion)
Use with caution in patients with biliary obstruction
Patients under anesthesia not studied
Use in both eyes concurrently not studied (if required, apply to the agressive lesion first followed by the second eye a week later; may apply concurrently to both eyes thereafter)
Use precaution to avoid extravasation (stop infusion immediately if it occurs)
Safety and efficacy of use >2 years not established
Patients who experience severe decrease of vision of 4 lines or more within 1 week, following treatment, should not be retreated, at least until vision completely recovers to pretreatment levels and potential benefits and risks of subsequent treatment are carefully considered by treating physician
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Distributed in milk; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Produces oxygen free radicals in presence of light that damage neovascular endothelium, which in turn leads to temporary vessel occlusion
Half-Life: 5-6 hr
Metabolism: To a small extent by liver and plasma esterases to a diacid metabolite that exhibits pharmacologic activity similar to that of verteporfin
Reconstitute 15 mg drug with 7 mL SWI to obtain a 2 mg/mL opaque dark-green solution
Protect from light & use within 4 hr
Further dilute in D5W to match 6 mg/sq.meter dose and infusion volume of 30 mL
After dilution protect from light & use within 4 hr
Infuse the 30 mL solution at rate of 3 mL/min over 10 min
Large antecubital veins are preferred to avoid extravasation
Stop infusion immediately & apply cold compresses
Protect extravasation site from light
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs